Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Researchers studied the medical records of more than 1 million children and young adults aged 2 to 24 who were taking or had taken stimulants such as Ritalin or Adderall and found no sign of increased risk of heart problems. “We don’t see any evidence of increased risk,” said Dr. William Cooper of Vanderbilt University, whose study was published in the New England Journal of Medicine. The study in children is the first of three commissioned by the Food and Drug Administration to understand the potential heart risks of the drugs after U.S. and Canadian regulators received a number of reports in 2006 of heart attacks, strokes and sudden cardiac arrest in children taking the medications. The reports prompted several FDA advisory committee hearings on heart problems, and Health Canada temporarily suspended marketing of ADHD drugs. The concerns also prompted the American Heart Association to issue guidelines suggesting that children who were just starting to take the drugs should be tested for potential underlying heart problems. “There was a lot of concern and confusion among families and providers about what the best approach would be to treating kids who had ADHD and who might benefit from these medicines,” Cooper said by phone. ADHD is one of the most common child mental disorders, affecting around 3 to 5 percent of children globally. Children with ADHD are excessively restless, impulsive and easily distracted, and often have trouble at home and in school. There is no cure, but the symptoms can be kept in check by a combination of behavioral therapy and medication. In the United States, some 2.7 million children have prescriptions for ADHD drugs including Novartis’ Ritalin or methylphenidate and Focalin; Johnson & Johnson’s Concerta, Shire’s Adderall and Vyvanse and Eli Lilly’s Strattera. For the study, Cooper’s team used prescription data from four large, geographically and demographically diverse health plans on 1,200,438 children and youth, including both current and past users of the drugs. They checked health records for evidence of heart problems, including heart attacks, strokes and sudden cardiac deaths, in children who were currently taking the drugs or who had taken them. The team found no increased risk of heart problems for either current or past users of the drugs. Yet because there were so few cases of serious heart problems — just 81 — the study may not have been large enough to detect it. But even if there were a risk of heart problems, it is extremely slight, Cooper said. In a guidance document issued on Tuesday, the FDA said it continues to recommend that the drugs not be used in patients with serious heart problems. It added that patients should be monitored for changes in heart rate or blood pressure. Jefferies analyst Peter Welford said the findings will likely reassure investors in Shire, maker of Adderall and Vyvanse. But because there were so few heart problems, the study was underpowered and cannot conclusively dispel concerns about cardiovascular risks. Shire’s shares were flat on Tuesday, outperforming a sharply lower market.
ADHD drugs do not increase heart problems in kids.

One in five people are drinking too much alcohol. 21% of adults aged 16+ in England reported to an NHS Digital survey that they usually drank more than the recommended 14 units of alcohol a week in 2017. Alcohol deaths in England at record high after 6% rise in a year. Correct, in terms of deaths that are a direct result of alcohol misuse. However, the number of alcohol-specific deaths per 100,000 people has remained virtually the same over the last ten years. Claim 1 of 3
Alcohol deaths in England at record high after 6% rise in a year.

The Oxford University team’s experimental product, called “ChAdOx1 nCoV-19”, is a type known as a recombinant viral vector vaccine and is one of at least 70 potential COVID-19 candidate shots under development by biotech and research teams around the world. At least five of those are in preliminary testing in people. The Oxford scientists said on Friday they were recruiting volunteers for early stage - Phase 1 - human trials of their shot, and large-scale production capacity was being put in place “at risk”. This means the shots will be produced in large numbers at risk of being useless if trials show they do not work. “We have started at risk manufacturing of this vaccine not just on a smallish scale ... but with a network of manufacturers in as many as seven different places around the world,” Adrian Hill, a professor and director of the Jenner Institute at Oxford University, told reporters in an online briefing. “The aim is to have at least a million doses by around about September, when we also hope to have efficacy (trial) results.”  He said three of the manufacturing partners were in Britain, two in Europe, one in India and one in China. The scientists said initial manufacturing costs would be in “tens of millions” of pounds and acknowledged the investment risk of pressing ahead with production before verification. They did not give details of their financing. More than 2.14 million people have been reported to be infected by the novel coronavirus globally and 143,744 have died, according to a Reuters tally. Hill’s team said they plan to start safety and then mid-stage efficacy trials of their potential COVID-19 vaccine in adults aged between 18 and 55 within weeks. They then plan to expand the trial group to older age groups later, and hope to run a final phase trial with around 5,000 volunteers in the late summer. Hill and his co-researchers - including Sarah Gilbert, an Oxford professor of vaccinology - said they have “a high degree of confidence” that human trials of the ChAdOx1 shot will show positive results in protecting against COVID-19 infection. They acknowledged that many other research teams worldwide were also working on potential vaccines, with only a proportion likely to be fully successful. “We can never be certain these things are going to work,” Gilbert told the briefing. “My view is that I think this one has a very strong chance of working.”  Asked when the shot - if proven to work - might be able to be made widely available to the public, Hill said the best case scenario would be for regulators to grant it “emergency use approval” - something that could be achieved within six weeks beyond the point at which data show whether it is effective. That, he said, could mean around six weeks from September, when the team hopes to have positive trial data.

UK scientists to make a million potential COVID-19 vaccines before proof.